United Therapeutics Corporation

UTHR.US
Healthcare · Drug Manufacturers - Specialty & Generic
523.63
-4.31 (-0.82%)
USD · NASDAQ

Company Information

Company Name
United Therapeutics Corporation
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
NASDAQ
ISIN: US91307C1027
CIK: 0001082554
CUSIP: 91307C102
Currency: USD
Full Time Employees: 1,400
Phone: 301 608 9292
Fiscal Year End: December
IPO Date: Jun 17, 1999
Description:

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.

Address:

1000 Spring Street, Silver Spring, MD, United States, 20910

People

Directors & Officers

Name Title Year Born
Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D. Founder, Chairman & CEO 1955
Mr. Michael I. Benkowitz President & COO 1972
Mr. James C. Edgemond CFO & Treasurer 1968
Mr. Paul A. Mahon J.D. Executive VP, General Counsel & Corporate Secretary 1964
Harrison Silvers Manager of Investor Relations NA
Ms. Holly Hobson Associate Vice President of Human Resources NA
Dr. Leigh Peterson Executive Vice President of Product Development & Xenotransplantation NA
Mr. Gil Golden Senior VP & Chief Medical Officer NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Apr 24, 2026 Christopher Patusky N/A Sale 2.91K $569.00 $1.66M
Apr 23, 2026 James Edgemond N/A Sale 9.64K $572.21 $5.51M
Apr 22, 2026 James Edgemond N/A Sale 364.00 $575.85 $209.61K
Apr 22, 2026 Martine A Rothblatt N/A Sale 9.50K $576.56 $5.48M
Apr 20, 2026 James Edgemond N/A Sale 10.00K $577.86 $5.78M
Apr 20, 2026 Martine A Rothblatt N/A Sale 9.50K $577.83 $5.49M
Apr 17, 2026 Christopher Patusky N/A Sale 1.00K $578.88 $578.88K
Apr 17, 2026 Martine A Rothblatt N/A Sale 9.50K $586.66 $5.57M
Apr 16, 2026 James Edgemond N/A Sale 10.00K $577.18 $5.77M
Apr 16, 2026 Paul A Mahon N/A Sale 8.30K $576.82 $4.79M
Apr 15, 2026 Martine A Rothblatt N/A Sale 9.50K $580.36 $5.51M
Apr 13, 2026 James Edgemond N/A Sale 10.00K $574.88 $5.75M
Apr 13, 2026 Martine A Rothblatt N/A Sale 9.50K $574.86 $5.46M
Apr 10, 2026 Martine A Rothblatt N/A Sale 9.50K $569.28 $5.41M
Apr 09, 2026 James Edgemond N/A Sale 10.00K $577.89 $5.78M
Apr 08, 2026 Martine A Rothblatt N/A Sale 9.50K $580.45 $5.51M
Apr 06, 2026 James Edgemond N/A Sale 10.00K $558.40 $5.58M
Apr 06, 2026 Martine A Rothblatt N/A Sale 9.50K $558.41 $5.30M
Apr 02, 2026 James Edgemond N/A Sale 10.00K $561.50 $5.62M
Apr 02, 2026 Paul A Mahon N/A Sale 8.30K $565.87 $4.70M

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
BlackRock Inc 5.40M Mar 31, 2026 12.72% $0.06 4.43%
Vanguard Group Inc 4.18M Dec 31, 2025 9.84% $0.03 -5.49%
venBio Select Advisor LLC 2.63M Mar 31, 2026 6.20% $15.34 0.92%
Wellington Management Company LLP 2.26M Mar 31, 2026 5.33% $0.25 -7.26%
Vanguard Portfolio Management, LLC 2.00M Mar 31, 2026 4.72% $0.06 0.00%
Vanguard Capital Management, LLC 1.96M Mar 31, 2026 4.61% $0.03 0.00%
State Street Corp 1.84M Mar 31, 2026 4.34% $0.04 0.08%
Renaissance Technologies Corp 1.79M Mar 31, 2026 4.21% $1.66 -6.40%
Geode Capital Management, LLC 1.23M Mar 31, 2026 2.90% $0.05 3.35%
HHG PLC 866.93K Mar 31, 2026 2.04% $0.25 8.90%
AQR Capital Management LLC 826.23K Mar 31, 2026 1.95% $0.22 -35.54%
Genworth Financial Wealth Mgmt Inc 616.05K Mar 31, 2026 1.45% $0.74 -2.98%
Amvescap Plc. 608.37K Mar 31, 2026 1.43% $0.04 -0.06%
NORGES BANK 602.19K Dec 31, 2025 1.42% $0.03 26.81%
FMR Inc 528.35K Mar 31, 2026 1.24% $0.02 30.83%
Dimensional Fund Advisors, Inc. 512.74K Mar 31, 2026 1.21% $0.06 -2.93%
Deerfield Management Co 457.00K Mar 31, 2026 1.08% $3.20 7.28%
Northern Trust Corp 436.57K Mar 31, 2026 1.03% $0.03 4.34%
Baillie Gifford & Co Limited. 428.13K Mar 31, 2026 1.01% $0.26 32.54%
Morgan Stanley - Brokerage Accounts 409.29K Mar 31, 2026 0.96% $0.01 5.14%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 iShares Core S&P Mid-Cap ETF 1.44M 3.40% ▼ 0.54% Jun 30, 2026
2 Vanguard Total Stock Mkt Idx Inv 1.35M 3.18% ▼ 3.37% Jun 30, 2026
3 Vanguard Small Cap Index 973.49K 2.29% ▼ 3.48% Jun 30, 2026
4 Vanguard Health Care Inv 855.74K 2.02% ▼ 12.21% Mar 31, 2026
5 Vanguard Institutional Extnd Mkt Idx Tr 487.03K 1.15% ▲ 0.04% Jun 30, 2026
6 State Street® SPDR® S&P MIDCAP 400® ETF 326.57K 0.77% ▲ 1.24% Jun 30, 2026
7 Vanguard Small Cap Value Index Inv 308.97K 0.73% ▼ 52.45% Jun 30, 2026
8 Vanguard US Growth Investor 304.13K 0.72% ▲ 63.33% Mar 31, 2026
9 iShares Biotechnology ETF 293.84K 0.69% ▲ 1.05% Jun 30, 2026
10 Vanguard Small Cap Growth Index Inv 281.18K 0.66% ▲ 0.00% Jun 30, 2026

Financial Highlights

Market Cap: $26.08B
EBITDA: $1.55B
P/E Ratio: $19.35
PEG Ratio: $2.22
Book Value: $139.98
Earnings/Share: $27.06
Profit Margin: 40.62%
Operating Margin: 41.69%
ROA (TTM): 12.62%
ROE (TTM): 20.26%
Revenue (TTM): $3.17B
Revenue/Share (TTM): $72.12
Earnings Growth (YOY): -12.20%
Revenue Growth (YOY): -1.60%

Valuation Metrics

Enterprise Value: $19.27B
Trailing P/E: 19.35
Forward P/E: 19.19

Shares Statistics

Shares Outstanding: 49.80M
Shares Float: 38.91M
% Insiders: 205.00%
% Institutions: 10,180.20%
Short % Float: 5.76%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$3.18B
Cost of Goods Sold
adjust
$-384.40M
Gross Profit
subtotal
$2.80B
SG&A
adjust
$-612.50M
R&D
adjust
$-550.00M
Other Operating Expense
adjust
$-118.60M
Operating Income
subtotal
$1.52B
Other / Non-Operating Items
adjust
$-182.50M
Net Income
subtotal
$1.33B

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about UTHR.US!